Notably, pCR was numerically higher in subgroups of patients with higher tumor PD-L1 expression and in the subgroup of patients with ER positivity <10% (who have previously been reported to have biological characteristics and clinical outcomes similar to those of patients with TNBC11–14). The gene discussed is ESR1; the disease is neoplasm.